Drug Profile
Research programme: cancer vaccines - Dynavax Technologies
Alternative Names: TLR9-adjuvanted nanoparticle cancer vaccine - Dynavax TechnologiesLatest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Dynavax Technologies
- Class Antigens; Antineoplastics; Oligonucleotides; Peptide vaccines
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants; Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Cancer in USA (Intratumoural)
- 01 Apr 2017 Preclinical trials in Cancer in USA (Intratumoural)
- 01 Apr 2017 Preclinical data in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)